【摘要】：神經(jīng)生長因子(nerve growth factor,NGF)是在1952年由Levi-Montalcini等人發(fā)現(xiàn)的,并因此獲得1986年諾貝爾生理學(xué)獎。NGF是最重要的神經(jīng)營養(yǎng)因子之一,在神經(jīng)、免疫、造血、生殖及內(nèi)分泌等系統(tǒng)均有重要生物學(xué)作用,尤其在神經(jīng)系統(tǒng)的作用已被公認(rèn)。NGF對調(diào)節(jié)神經(jīng)元的生長、發(fā)育、分化、存活及神經(jīng)損傷的再生修復(fù)均具有重要作用,在Alzheimer's病、神經(jīng)損傷等神經(jīng)系統(tǒng)疾病中已證實有較好的療效。NGF由三個亞基(α、β和γ)組成,NGF的生物學(xué)活性集中體現(xiàn)在β亞基上,因此又稱為β-NGF。目前,NGF基因及其蛋白的生物學(xué)功能和臨床應(yīng)用研究仍是神經(jīng)科學(xué)領(lǐng)域的重要課題之一。天然NGF可從表達(dá)豐富的動物組織中直接提取,但含量均相對較低,難以滿足臨床應(yīng)用,直到近年來,人工重組NGF的問世,才基本解決了此問題。但因為NGF是大分子蛋白,不易透過血腦屏障,故治療受到限制。因此,選擇合適的給藥方法是當(dāng)前需要解決的重大課題,基因治療方法是目前最有希望的方案之一。 目前,人們對用于細(xì)胞移植和基因治療的供體細(xì)胞的研究較多,骨髓間充質(zhì)干細(xì)胞(bone marrow mesenchymal stem cells,BMSCs)是一群具有向成骨細(xì)胞,成脂肪細(xì)胞,肝臟細(xì)胞,心肌細(xì)胞和神經(jīng)細(xì)胞等多種細(xì)胞分化的多潛能組織干細(xì)胞。由于它具有:①容易獲取、培養(yǎng);②可穿越血腦屏障,長期存活;③能有效地表達(dá)外源性基因;④移植后植入反應(yīng)較弱等特點(diǎn)。因此,BMSCs成為細(xì)胞治療和基因治療的種子細(xì)胞,顯示出廣闊的應(yīng)用前景。本研究的目的在于構(gòu)建人β-NGF基因
[Abstract]:Nerve growth factor (nerve growth factor,NGF) was discovered by Levi-Montalcini et al in 1952 and won the 1986 Nobel Prize in Physiology. NGF is one of the most important neurotrophic factors in nerve, immunity and hematopoiesis. Reproductive and endocrine systems play important biological roles, especially in the nervous system. NGF plays an important role in regulating the growth, development, differentiation, survival and regeneration of nerve injury in Alzheimer's disease. NGF is composed of three subunits (偽, 尾 and 緯). The biological activity of NGF is concentrated on 尾 subunit, so it is also called 尾-NGF.. At present, the biological function and clinical application of NGF gene and its protein are still one of the important subjects in the field of neuroscience. Natural NGF can be extracted directly from animal tissues with abundant expression, but the content is relatively low, so it is difficult to meet the clinical application. In recent years, artificial recombinant NGF has not been able to solve this problem. However, treatment is limited because NGF is a macromolecular protein that does not easily penetrate the blood-brain barrier. Therefore, the choice of appropriate drug delivery method is an important issue to be solved. Gene therapy is one of the most promising methods. At present, there are many researches on donor cells used in cell transplantation and gene therapy. Bone marrow mesenchymal stem cells (bone marrow mesenchymal stem cells,BMSCs) are a group of osteoblasts, adipoblasts, liver cells. Multipotent tissue stem cells differentiated from cardiomyocytes and nerve cells. Because it is easy to obtain and culture, it can cross the blood-brain barrier and survive for a long time, it can express exogenous genes effectively, and the implantation response is weak after transplantation. Therefore, BMSCs is a seed cell for cell therapy and gene therapy. The aim of this study is to construct human 尾-NGF gene.
【學(xué)位授予單位】：鄭州大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2005
【分類號】：R346

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 魚兵,范清宇,馬保安,周勇,張明華,龍華,閆露;人骨形成蛋白-7基因重組腺病毒的構(gòu)建及其在兔骨髓間充質(zhì)干細(xì)胞中的表達(dá)[J];第四軍醫(yī)大學(xué)學(xué)報;2004年17期

2 李建軍,楊紹娟,卜麗莎,高申,張文嵐,崔亞南,王宏,劉建國,徐莘香;BMP-2基因轉(zhuǎn)染的人骨髓基質(zhì)干細(xì)胞復(fù)合PLA/PCL支架體外構(gòu)建組織工程骨[J];骨與關(guān)節(jié)損傷雜志;2004年03期

3 高燕玲 ,徐艷;前列地爾和神經(jīng)生長因子治療糖尿病神經(jīng)病變臨床觀察[J];廣西醫(yī)學(xué);2003年01期

4 張素,陳崇宏,鄭志，

本文編號：2414777